Skip to main content

Advertisement

Table 2 Antirheumatic agents and aminotransferase concentrations in 77 rheumatoid arthritis patients

From: Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis

Characteristic Mean [95% CI] or n (%)
Antirheumatic agents in 34 methotrexate naïve patients  
   Non-steroidal antiinflammatory agents 14 (41)
   Prednisone users 4 (12)
   Prednisone dose (mg/l)* 1.2 [1.0–1.4]
   Disease modifying agents  
Users 13 (38)
Leflunomide 6 (18)
Chloroquine 5 (15)
Sulphasalazine 3 (9)
Azathioprine 2 (6)
Antirheumatic agents in 43 patients before methotrexate use  
   Non-steroidal antiinflammatory agents 32 (74)
   Prednisone users 17 (40)
   Prednisone dose (mg/l)* 2.4 [1.7–3.4]
   Disease modifying agents  
Users 13 (30)
Sulphasalazine 10 (23)
Chloroquine 3 (7)
Antirheumatic agents in 43 patients using methotrexate  
   Non-steroidal antiinflammatory agents 20 (48)
   Prednisone users 7 (16)
   Prednisone dose (mg/l)* 1.0 [1.1–1.5]
   Disease modifying agents  
Methotrexate dose (mg/week) 19.6 [17.5–21.7]
Chloroquine 21 (49)
Minocyclin 12 (28)
Leflunomide 5 (12)
Sulphasalazine 4 (9)
Azathioprine 3 (7)
Aminotransferase levels in 34 methotrexate naïve patients  
   Alanine aminotransferase (u/l) 27 [22–31]
   Aspartate aminotransferase (u/l) 23 [22–25]
Aminotransferase levels in 43 patients before methotrexate use  
   Alanine aminotransferase (u/l) 19 [17–22]
   Aspartate aminotransferase (u/l) 20 [18–22]
Aminotransferase levels in 43 patients using methotrexate  
   Alanine aminotransferase (u/l) 38 [33–42]
   Aspartate aminotransferase (u/l) 30 [27–34]
Increases in aminotransferase levels in 43 patients on methotrexate  
   Alanine aminotransferase (u/l) 18 [14–23]
   Aspartate aminotransferase (u/l) 11 [7–14]
Change in weight in 43 patients since using methotrexate (kg) -0.7 [-0.2–0.6]
Duration of methotrexate therapy in 43 patients (years) 5.1 [4.1–6.1]
  1. *Variables for which geometric means [95% CI] are given. p < 0.0001; p = 0.7.